An interventional study of quality of life assessment in Breast Cancer and Melanoma, sponsored by Institut Cancerologie de l'Ouest. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-02.
Sponsored by Institut Cancerologie de l'Ouest · Not applicable, Interventional, and Other
Generally, French studies concerned with the quality of life of cancer patients focus on the period of treatment (up to 2 years post diagnosis). However, studies about quality of life "after" cancer are relatively rare (= long-term quality of life, or from 5 years post diagnosis). These studies mainly concern the most common cancers (breast and prostate).
Or changes in quality of life after treatment could be different depending on the type of cancer. In addition, there is a significant influence of sociodemographic variables on the quality of life in remission.
Similarly using remote diagnostics, quality of life questionnaires related to health, must be reassessed because too often developed for situations in process.
Based on these findings, "ELCCA II" study proposes to study for five years, the evolution of the impacts of two types of cancer (breast and melanoma) on quality of life (overall and related to the subjective health), socioeconomic status, and behavioral and emotional dimensions (post-traumatic development, coping, anxiety-depression) of those treated.
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's enrollment of 314 is above the median of 38 across 2,351 interventional studies indexed under Melanoma.
Browse Melanoma studies →Institut Cancerologie de l'Ouest is the lead sponsor of 105 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
Other: quality of life assessment
All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis. Those assessment will use standardized quality of life questionnaire : * QLQ-C30 * SWLS (Satisfaction with Life Scale) * PTGI (Post-Traumatic Growth Inventory) * HADS (Hospital Anxiety and Depression Scale) * Brief COPE * MHLCS (Multidimensional Health Locus of Control Scale)
long term evolution of quality of life for patient with breast cancer or melanoma
The evolution of quality of life will be assess with standardized quality of life questionnaire
Time frame: 5 years after initial cancer diagnostics
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Cancerologie de l'Ouest